Industry Reports >> Pharmaceuticals and Healthcare >> Therapy Area

Browse the latest reports in the therapy area industry below. You can sort your results by publication date, by price or alphabetically

Sort By:
Report Status:
7680 Report Results
Page 1 of 308
Go To Page:
    
  Go

EpiCast Report: Ankylosing Spondylitis – Epidemiology Forecast to 2024

$3,995.00
By:
, Published: Aug-2015
Ankylosing spondylitis (AS) - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis (SpA) and one of the most common rheumatic diseases across the globe. AS primarily affects the spine and sacroiliac (SI) joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any s.....

OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024

$9,495.00
By:
, Published: Aug-2015
GlobalData estimates the 2014 sales for the Fabry disease market at approximately $682m across the 7MM. The US contributed the majority of these sales, generating an estimated $295m. By the end of the forecast period in 2024, Fabry disease sales are expected to grow to $1.25 billion at a Compound Annual Growth Rate (CAGR) of 6.3% over the 10-year period. The majority of sales in the 7MM in 2024 will come from the US, which will represent 44.2% o.....

OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecast to 2024

$9,495.00
By:
, Published: Aug-2015
GlobalData estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sales of approximately $1.88 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.88% and generating around 59% of global sales in 2024. The majo.....

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast 2014 to 2024

$3,995.00
By:
, Published: Aug-2015
Growth hormone deficiency (GHD) is an endocrine disorder characterized by low or deficient secretion of growth hormone (GH) secondary to malfunction of the pituitary gland, a pea-sized structure located at the base of the brain that is responsible for the production of GH. The International Classification of Diseases (ICD-10) ICD-10–CM code for GHD is E23.0. GHD in children can be classified as idiopathic or organic, which is further divided int.....

OpportunityAnalyzer: Axial Spondyloarthritis – Opportunity Analysis and Forecast to 2024 - Event Driven Update

$9,495.00
By:
, Published: Jul-2015
Ankylosing Spondylitis (AS) is an autoimmune disease that causes inflammation of the sacroiliac joint accompanied by pain and stiffness of the lower back, which typically gets better with exercise. Ankylosis (fusion) of the spine is typically a late-stage complication and has been nicknamed “bamboo spine”, due to its appearance on X-ray. It is now recognized that the pathological changes leading to ankylosis develop over time, and an early stage.....

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

$4,995.00
By:
, Published: Jul-2015
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, aware.....

EpiCast Report: Multiple Myeloma – Epidemiology Forecast to 2023

$3,995.00
By:
, Published: Jul-2015
Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma cell. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but multiple myeloma causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. Rather than producing helpful antibodies, the cancer cells .....

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

$4,995.00
By:
, Published: Jul-2015
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market wer.....

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

$4,995.00
By:
, Published: Jul-2015
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher.....

OpportunityAnalyzer: Genital Herpes – Opportunity Analysis and Forecasts to 2023

$9,495.00
By:
, Published: Jul-2015
Genital herpes (GH) is a life-long viral infection of the genitalia and urogenital tract. It is one of the most common sexually transmitted infections (STIs) and is a leading cause of genital ulcers around the world. Patients with GH can suffer from recurring episodes of symptom outbreaks, which usually involve painful ulcerations. The prevalence of GH in the seven major pharmaceutical markets (7MM) covered in this report (US, France, Germany, It.....

Life Cycle Management Strategies – Optimizing revenues and defending generic competition

$2,995.00
By:
, Published: Jul-2015
GBI Research’s latest report “Life Cycle Management Strategies – Optimizing Revenues and Defending Generic Competition” discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategi.....

EpiCast Report: Genital Herpes – Epidemiology Forecast to 2023

$3,995.00
By:
, Published: Jul-2015
Genital herpes is a chronic, sexually transmitted infection caused by the herpes simplex virus (HSV) and is the primary cause of genital ulcers. Genital herpes can also be vertically transmitted from a mother to her newborn during birth, leading to a high risk of mortality in infants. HSV has two forms: HSV-1 and HSV-2. The majority of genital herpes cases globally are caused by HSV-2, although approximately half of all new cases in developed cou.....

Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation

$6,995.00
By:
, Published: Jul-2015
The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,.....

Malignant Mesothelioma Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H2, 2015" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by re.....

Acute Pharyngitis Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Acute Pharyngitis Global Clinical Trials Review, H2, 2015" provides an overview of Acute Pharyngitis clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Pharyngitis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (.....

Ancylostomiasis (Hookworm Infections) Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Ancylostomiasis (Hookworm Infections) Global Clinical Trials Review, H2, 2015" provides an overview of Ancylostomiasis (Hookworm Infections) clinical trials scenario. This report provides top line data relating to the clinical trials on Ancylostomiasis (Hookworm Infections) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report off.....

Bronchiectasis Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Bronchiectasis Global Clinical Trials Review, H2, 2015" provides an overview of Bronchiectasis clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiectasis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7),.....

Bronchospasm Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Bronchospasm Global Clinical Trials Review, H2, 2015" provides an overview of Bronchospasm clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchospasm . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase.....

Cardiogenic Shock Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Cardiogenic Shock Global Clinical Trials Review, H2, 2015" provides an overview of Cardiogenic Shock clinical trials scenario. This report provides top line data relating to the clinical trials on Cardiogenic Shock . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (.....

Cervical Dysplasia Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Cervical Dysplasia Global Clinical Trials Review, H2, 2015" provides an overview of Cervical Dysplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Cervical Dysplasia . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, countr.....

Hyperphosphatemia Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Hyperphosphatemia Global Clinical Trials Review, H2, 2015" provides an overview of Hyperphosphatemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7.....

Lung Injury Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H2, 2015" provides an overview of Lung Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, tri.....

Malnutrition Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Malnutrition Global Clinical Trials Review, H2, 2015" provides an overview of Malnutrition clinical trials scenario. This report provides top line data relating to the clinical trials on Malnutrition. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, .....

Nasal Congestion Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Nasal Congestion Global Clinical Trials Review, H2, 2015" provides an overview of Nasal Congestion clinical trials scenario. This report provides top line data relating to the clinical trials on Nasal Congestion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & .....

Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2015

$2,500.00
By:
, Published: Jul-2015
GlobalData's clinical trial report, “Obstructive Pulmonary Disease Global Clinical Trials Review, H2, 2015" provides an overview of Obstructive Pulmonary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Obstructive Pulmonary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease cl.....